Demant A/S (OTCMKTS:WILYY) Sees Strong Trading Volume – Time to Buy?

Demant A/S Unsponsored ADR (OTCMKTS:WILYY) saw an uptick in trading volume on Thursday . 1,400 shares were traded during mid-day trading, an increase of 165% from the previous session’s volume of 529 shares.The stock last traded at $22.50 and had previously closed at $22.58.

Wall Street Analysts Forecast Growth

WILYY has been the topic of several analyst reports. UBS Group downgraded shares of Demant A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. Morgan Stanley upgraded Demant A/S from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, June 23rd. Sanford C. Bernstein lowered Demant A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 17th. Finally, Zacks Research raised Demant A/S to a “hold” rating in a report on Friday, June 26th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy”.

Demant A/S Price Performance

The company has a quick ratio of 1.00, a current ratio of 1.36 and a debt-to-equity ratio of 1.65. The business’s fifty day simple moving average is $20.51 and its 200 day simple moving average is $17.48.

About Demant A/S

Demant A/S is a Denmark-based global hearing health care company specializing in the development, manufacture and distribution of hearing solutions and audiological diagnostic instruments. The company’s flagship brands include Oticon, Bernafon and Sonic, which offer a range of hearing aids designed to address various levels of hearing loss. In addition to personal hearing devices, Demant provides diagnostic equipment such as audiometers and tympanometers, supporting hearing care professionals in accurate assessment and fitting of hearing solutions.

Beyond hearing aids and diagnostics, Demant’s product portfolio extends to hearing implants—cochlear and bone-anchored systems—through its Oticon Medical division.